Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Heparin Immunogenicity Guidance Addresses ANDA Approvals, Brand Changes

Executive Summary

Guidance formalizes five criteria FDA used in making a “sameness” determination for Momenta/Sandoz’s enoxaparin ANDA and lays out an approach to assessing the effect of post-approval NDA changes on a product’s immunogenicity without the need for clinical trials.

Advertisement

Related Content

Lilly Preps To File A Rival To Lantus, But Safety Remains In Question
Lilly Preps To File A Rival To Lantus, But Safety Remains In Question
FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics
Lovenox Generics: FDA’s Split Opinion On ANDA Approval Fully Supported By Court
Generic Lovenox Battle Heats Up With Amphastar’s ANDA Approval
FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS056051

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel